Presence of multiple abnormal immunologic markers is an independent prognostic factor of diffuse large B-cell lymphoma

Autoimmune diseases (ADs) increase the risk of non-Hodgkin's lymphoma and contribute to poor prognosis of patients. However, the association between immunologic markers and clinical outcome has rarely been investigated. This study aims to analyze the prognostic value of pretreatment immunologic...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers of medicine 2019-02, Vol.13 (1), p.94-103
Main Authors: Cao, Yiwen, Liu, Zhenhua, Wu, Wen, Qian, Ying, Shi, Qin, Shen, Rong, Ouyang, Binshen, Xu, Pengpeng, Cheng, Shu, Ye, Jin, Lu, Yiming, Wang, Chaofu, Yang, Chengde, Wang, Li, Zhao, Weili
Format: Article
Language:English
Subjects:
Autoimmune diseases
Cancer therapies
diffuse large B-cell lymphoma
Disease
Hospitals
immunologic marker
Lupus
Lymphoma
Medical prognosis
Medicine
Medicine & Public Health
Pathogenesis
prognosis
Research Article
Rheumatoid arthritis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Autoimmune diseases (ADs) increase the risk of non-Hodgkin's lymphoma and contribute to poor prognosis of patients. However, the association between immunologic markers and clinical outcome has rarely been investigated. This study aims to analyze the prognostic value of pretreatment immunologic markers in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). We retrospectively reviewed the data on 502 patients with DLBCL treated in our institution from January 2013 to March 2018. Survival functions were estimated using Kaplan-Meier method and Cox regression model. The 3-year progression free survival (PFS) and overall survival (OS) rates were 70.2% and 80.9%, respectively, and the complete remission (CR) rate was 78.1%. Among the patients, those with multiple (≥3) abnormal immunologic markers had significantly shorter 3-year PFS (52.7% vs. 77.3%, P
ISSN:2095-0217
2095-0225
DOI:10.1007/s11684-019-0680-1